Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05036291 | A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06779851 | A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors(SUMMIT-1) | terminated | Phase 1 | 20 | Bright Peak Therapeutics IncINDUSTRY | 1 | Apr 22, 2026 |
| clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | terminated | Phase 1 / Phase 2 | 110 | Tango Therapeutics, Inc.INDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 188 | Ascendis Pharma Oncology Division A/SINDUSTRY | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05879627 | To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors | terminated | Phase 1 | 93 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | terminated | Phase 1 | 91 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05262530 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | terminated | Phase 1 / Phase 2 | 73 | BioNTech SEINDUSTRY | 4 | Apr 8, 2026 | clinicaltrials |
| NCT04931823 | Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 34 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation(ALAFOSS-01) | terminated | Phase 1 | 17 | AstraZenecaINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 11 | PfizerINDUSTRY | 5 | Mar 18, 2026 | clinicaltrials |
| NCT06540066 | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 35 | BeiGeneINDUSTRY | 3 | Mar 16, 2026 | clinicaltrials |
| NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | terminated | Phase 1 | 99 | BeiGeneINDUSTRY | 5 | Mar 13, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | terminated | Phase 1 | 17 | Accent TherapeuticsINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05381909 | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors | terminated | Phase 1 | 157 | BeiGeneINDUSTRY | 5 | Feb 20, 2026 | clinicaltrials |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 21 | PfizerINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | terminated | Phase 1 | 64 | Mirati Therapeutics Inc.INDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT05100251 | Clinical Trial of WBC100 on Advanced Solid Tumor | terminated | Phase 1 | 68 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05638334 | Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06331559 | Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors | terminated | Phase 1 | 13 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT06457997 | A Study of PHN-010 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | Pheon TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT05868915 | HV-101 for Patients With Advanced Solid Tumors | terminated | Phase 1 | 1 | Hervor TherapeuticsINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06334783 | TIL for Patients With Advanced Solid Tumor | terminated | Phase 1 | 5 | Hervor TherapeuticsINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06560632 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors(POLAR) | terminated | Phase 1 | 26 | Repare TherapeuticsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04284488 | Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT06337630 | A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors(POP-ART) | terminated | Phase 1 | 10 | Institut CurieOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06198426 | A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 2 | Dec 30, 2025 | clinicaltrials |
| NCT06488716 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 12 | Genentech, Inc.INDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT06509906 | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | terminated | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Dec 18, 2025 | clinicaltrials |
| NCT03968653 | Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | terminated | Phase 1 | 76 | Debiopharm International SAINDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05147272 | Study of RP-6306 With Gemcitabine in Advanced Solid Tumors | terminated | Phase 1 | 67 | Debiopharm International SAINDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT05147350 | Study of RP-6306 With FOLFIRI in Advanced Solid Tumors(MINOTAUR) | terminated | Phase 1 | 38 | Debiopharm International SAINDUSTRY | 4 | Dec 5, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Apr 22, 2026source: clinicaltrials